Ray-Coquard I, Wilson C, Moore K
Lancet . 2026 Feb 21;407(10530):743-744
doi: 10.1016/S0140-6736(25)02463-8
PMID: 41520675
ABSTRACT
IR-C received funding from AbbVie, Advaxis, Zentalis, Amgen, Clovis Oncology, Eisai, F. Hoffmann–La Roche, Regeneron Pharmaceuticals, ImmunoGen, Merck Sharp Dohme, Takeda, PharmaMar SA, GSK–Tesaro, Bristol Myers Squibb, and AstraZeneca; honoraria and expenses for consulting and participating on advisory boards from AstraZeneca, Clovis Oncology, Deciphera, Genmab–Pfizer, GSK, Immunogen–AbbVie, Mersana Therapeutics, PharmaMar, Merck Sharp Dohme, Agenus, SUTRO, Corcept Therapeutics, Novocure, Eisai, and Daiichi Sankyo; and travel and accommodation support from AstraZeneca, PharmaMar, and Roche. KM received honoraria or reimbursement for participating on scientific advisory boards from Aadi, AstraZeneca, AbbVie, BioNTech, Corcept, Caris, Duality, Daiichi–Sankyo, Eisai, GSK, Immunogen, Iovance, Janssen, Loxo–Lilly, Mersana, Merck, Novartis, Pannavance, Regeneron, Schrodinger, Takeda, Verastem, Whitehawk, Zentalis, and Zymeworks. CW is a Senior Medical Editor at The Lancet and declares no competing interests.
